TWI772261B - Pd-l1拮抗劑組合治療 - Google Patents

Pd-l1拮抗劑組合治療 Download PDF

Info

Publication number
TWI772261B
TWI772261B TW105118967A TW105118967A TWI772261B TW I772261 B TWI772261 B TW I772261B TW 105118967 A TW105118967 A TW 105118967A TW 105118967 A TW105118967 A TW 105118967A TW I772261 B TWI772261 B TW I772261B
Authority
TW
Taiwan
Prior art keywords
cancer
antibody
antagonist
administered
dose
Prior art date
Application number
TW105118967A
Other languages
English (en)
Chinese (zh)
Other versions
TW201709933A (zh
Inventor
格倫 伊恩 安德魯斯
士浩 陳
艾莉珊德拉 迪 皮托
大衛 佛塔納
納連娜 高伯格
家揚 林
華 龍
瑪席拉 馬丁吉奧尼
迪米里 瑟吉 安東尼 努坦
亞隆 大衛 泰爾
愛德瑞恩 沃弗森
Original Assignee
德商馬克專利公司
美商輝瑞大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商馬克專利公司, 美商輝瑞大藥廠 filed Critical 德商馬克專利公司
Publication of TW201709933A publication Critical patent/TW201709933A/zh
Application granted granted Critical
Publication of TWI772261B publication Critical patent/TWI772261B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW105118967A 2015-06-16 2016-06-16 Pd-l1拮抗劑組合治療 TWI772261B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562180543P 2015-06-16 2015-06-16
US62/180,543 2015-06-16
US201562219995P 2015-09-17 2015-09-17
US62/219,995 2015-09-17
US201662286501P 2016-01-25 2016-01-25
US62/286,501 2016-01-25
US201662337489P 2016-05-17 2016-05-17
US62/337,489 2016-05-17

Publications (2)

Publication Number Publication Date
TW201709933A TW201709933A (zh) 2017-03-16
TWI772261B true TWI772261B (zh) 2022-08-01

Family

ID=56236125

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105118967A TWI772261B (zh) 2015-06-16 2016-06-16 Pd-l1拮抗劑組合治療

Country Status (15)

Country Link
US (2) US10869924B2 (enExample)
EP (1) EP3310810A1 (enExample)
JP (2) JP6876629B2 (enExample)
KR (1) KR102712880B1 (enExample)
CN (1) CN107750166B (enExample)
AU (1) AU2016280003B2 (enExample)
CA (1) CA2989586A1 (enExample)
IL (1) IL256245B (enExample)
MX (1) MX390878B (enExample)
MY (1) MY193229A (enExample)
PH (1) PH12017501857B1 (enExample)
RU (1) RU2766890C2 (enExample)
TW (1) TWI772261B (enExample)
UA (1) UA126892C2 (enExample)
WO (1) WO2016205277A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
HK1248115A1 (zh) 2015-07-16 2018-10-12 Bioxcel Therapeutics, Inc. 一种使用免疫调节治疗癌症的新颖方法
PL3386541T3 (pl) 2015-12-07 2021-04-06 Merck Patent Gmbh Wodna formulacja farmaceutyczna zawierającą przeciwciało anty-pd-1 awelumab
EP3408294A1 (en) * 2016-01-25 2018-12-05 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
EP3522923A1 (en) * 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
AU2018206015B2 (en) * 2017-01-06 2019-05-30 Eutilex Co., Ltd. Anti-human 4-1 BB antibodies and use thereof
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US20200016267A1 (en) 2017-03-06 2020-01-16 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
EP3372615A1 (en) 2017-03-06 2018-09-12 Merck Patent GmbH Composition comprising avelumab
IL269718B2 (en) 2017-03-30 2024-10-01 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
CN110799540B (zh) * 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
TW201922793A (zh) * 2017-11-16 2019-06-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
MX2020007526A (es) * 2018-01-22 2020-09-09 Bristol Myers Squibb Co Composiciones y metodos para tratar el cancer.
CN111867679A (zh) * 2018-03-06 2020-10-30 居里研究所 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
CN112424225B (zh) * 2018-03-29 2023-08-11 桂林三金药业股份有限公司 抗pd-l1抗体及其用途
AU2018418224B2 (en) 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
CN112996910A (zh) * 2018-07-11 2021-06-18 动量制药公司 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021004348A (es) * 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
CN114340679A (zh) * 2018-10-31 2022-04-12 基因泰克公司 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
WO2020123477A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
CN113164599B (zh) * 2018-12-24 2023-08-01 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
US12421313B2 (en) 2019-01-25 2025-09-23 Chia Tia Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
EP3955925A4 (en) 2019-04-18 2023-03-22 QLSF Biotherapeutics Inc. HUMANIZED ANTI-PD-L1 ANTIBODIES
CN113905761A (zh) * 2019-06-10 2022-01-07 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
CN110746493A (zh) * 2019-09-06 2020-02-04 中国药科大学 一种pd-l1拮抗剂多肽及其应用
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
FI3884929T3 (fi) 2020-03-25 2023-08-07 Ocular Therapeutix Inc Tyrosiinikinaasi-inhibiittoria sisältävä silmäimplantti
CN115461079A (zh) * 2020-04-30 2022-12-09 正大天晴药业集团股份有限公司 用于治疗肾癌的联用药物
WO2022068894A1 (zh) * 2020-09-30 2022-04-07 上海齐鲁制药研究中心有限公司 同时靶向pd-l1和vegf的双功能分子及其医药用途
MX2023005930A (es) * 2020-11-26 2023-05-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000475A (en) 1908-12-31 1911-08-15 Rodney Robert Woodson Coal-mining pick.
US1013829A (en) 1911-04-17 1912-01-02 Narragansett Machine Company Vaulting-bar.
US1032309A (en) 1911-08-05 1912-07-09 Pembroke N Squires Headlight-adjuster for motor-vehicles.
US1057020A (en) 1912-03-18 1913-03-25 Robert C Wade Sectional smoke-burner.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
JPH07263576A (ja) 1994-03-25 1995-10-13 Hitachi Ltd 半導体集積回路装置およびその製造方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
CN1832743A (zh) * 2003-04-03 2006-09-13 美国辉瑞有限公司 包含ag013736的剂型
MXPA05009303A (es) 2003-04-03 2005-10-05 Pfizer Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
JP2008518904A (ja) 2004-11-02 2008-06-05 ファイザー・インク ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
EP1809621A1 (en) 2004-11-02 2007-07-25 Pfizer, Inc. Methods of preparing indazole compounds
WO2006048746A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for the removal of heavy metals
CA2586176A1 (en) 2004-11-02 2006-05-11 Srinivasan Babu Methods for preparing indazole compounds
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
SG186656A1 (en) 2007-12-14 2013-01-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077634A1 (en) * 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
WO2012012518A2 (en) * 2010-07-20 2012-01-26 University Of Miami Inhibition of nonsense mediated decay pathways
EP3264089A1 (en) 2010-08-31 2018-01-03 Genentech, Inc. Biomarkers and methods of treatment
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
CA3019531A1 (en) * 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
CA2845810C (en) 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
JP6483082B2 (ja) 2013-03-15 2019-03-13 ジェネンテック， インコーポレイテッド Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法
WO2014163684A1 (en) 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
KR102232153B1 (ko) * 2013-08-20 2021-03-24 머크 샤프 앤드 돔 코포레이션 Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
RU2701327C2 (ru) 2013-09-11 2019-09-25 Медиммьюн Лимитед Антитела к b7-h1 для лечения опухолей
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
JP6568093B2 (ja) 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
US20160303231A1 (en) 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
KR20160089532A (ko) 2013-12-17 2016-07-27 제넨테크, 인크. Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
KR102630750B1 (ko) 2013-12-17 2024-01-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
WO2015126903A1 (en) 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
EP3114144A1 (en) 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20170158776A1 (en) 2014-05-15 2017-06-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3309174B1 (en) 2014-07-11 2022-05-11 Ventana Medical Systems, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
CN112546238A (zh) * 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
KR20170101925A (ko) 2014-12-02 2017-09-06 셀진 코포레이션 병용 요법
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2017202744A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
EP3522923A1 (en) 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
IL269718B2 (en) 2017-03-30 2024-10-01 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Hu-Lowe DD et al. "Nonclinical Antiangiogenesis and AntitumorActivities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3" Clinical Cancer Research vol.14 no.22 American Association for Cancer 2008/11/15 p.7272-7283 *
期刊 Yasuda S et al. "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo" Clinical and Experimental Immunology vol.172 British Society for Immunology 2013/01/10 p.500-506; *

Also Published As

Publication number Publication date
IL256245A (en) 2018-02-28
PH12017501857B1 (en) 2024-01-17
CN107750166A (zh) 2018-03-02
EP3310810A1 (en) 2018-04-25
US20180169232A1 (en) 2018-06-21
JP2021113220A (ja) 2021-08-05
AU2016280003B2 (en) 2021-09-16
JP2018522850A (ja) 2018-08-16
CN107750166B (zh) 2022-02-11
MX2017016324A (es) 2018-03-02
RU2018101314A (ru) 2019-07-16
MY193229A (en) 2022-09-26
US20210069326A1 (en) 2021-03-11
HK1248530A1 (zh) 2018-10-19
CA2989586A1 (en) 2016-12-22
MX390878B (es) 2025-03-21
TW201709933A (zh) 2017-03-16
JP6876629B2 (ja) 2021-05-26
UA126892C2 (uk) 2023-02-22
WO2016205277A1 (en) 2016-12-22
KR20180018762A (ko) 2018-02-21
IL256245B (en) 2022-09-01
KR102712880B1 (ko) 2024-10-02
RU2766890C2 (ru) 2022-03-16
AU2016280003A1 (en) 2018-02-01
NZ737018A (en) 2021-11-26
US10869924B2 (en) 2020-12-22
PH12017501857A1 (en) 2018-02-26
RU2018101314A3 (enExample) 2020-01-29

Similar Documents

Publication Publication Date Title
TWI772261B (zh) Pd-l1拮抗劑組合治療
US20220324979A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
AU2017211540B2 (en) Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer
JP6586087B2 (ja) Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
EP3102604B1 (en) Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
CA2949214A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
KR20210006405A (ko) 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
NZ737018B2 (en) Pd-l1 antagonist combination treatments
BR112017027026B1 (pt) Usos de um antagonista de pd-l1 e de um inibidor de vegfr, medicamentos e kits compreendendo os mesmos
HK1248530B (en) Pd-l1 antagonist combination treatments
HK40010365A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK1228930A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer